fda compounding semaglutide enforcement november 2025 Important Notice: Tirzepatide Update FDA is short-sighted on compounding
Description
Further studies are required to determine the source of the differential effects of GIP signaling on obesity promotion by HFD, overeating, and menopause
Medications that mimic GLP-1 (such as semaglutide [Ozempic, Wegovy] and tirzepatide [Mounjaro]) have been shown to support safe, effective weight loss
When they are stopped, appetite signals may return
About 61% of GLP - 1 users in the study were taking the drugs to treat type 2 diabetes, while about 39% of users generally younger, wealthier and fewer clinically obese users were using them to manage their weight
Green has been voted one of New York Citys best dermatologists by publications such as Castle Connolly, New York Magazine, Super Doctors, and The New York Times
Heather McKenzie is a senior editor at BioSpace
